Orchid Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Orchid Pharma has a total shareholder equity of ₹12.2B and total debt of ₹1.6B, which brings its debt-to-equity ratio to 13.4%. Its total assets and total liabilities are ₹16.4B and ₹4.1B respectively. Orchid Pharma's EBIT is ₹934.7M making its interest coverage ratio -37.1. It has cash and short-term investments of ₹2.4B.
Key information
13.4%
Debt to equity ratio
₹1.64b
Debt
| Interest coverage ratio | -37.1x |
| Cash | ₹2.44b |
| Equity | ₹12.24b |
| Total liabilities | ₹4.11b |
| Total assets | ₹16.35b |
Recent financial health updates
Recent updates
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/E Is Still On The Mark Following 25% Share Price Bounce
Nov 27
Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%
Jul 29We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease
Jun 12Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price
May 08Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce
Feb 28Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?
Feb 06Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump
Dec 18Financial Position Analysis
Short Term Liabilities: ORCHPHARMA's short term assets (₹8.3B) exceed its short term liabilities (₹2.8B).
Long Term Liabilities: ORCHPHARMA's short term assets (₹8.3B) exceed its long term liabilities (₹1.3B).
Debt to Equity History and Analysis
Debt Level: ORCHPHARMA has more cash than its total debt.
Reducing Debt: ORCHPHARMA's debt to equity ratio has reduced from 6128.4% to 13.4% over the past 5 years.
Debt Coverage: ORCHPHARMA's debt is not well covered by operating cash flow (8.9%).
Interest Coverage: ORCHPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orchid Pharma Limited is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Angel Broking Private Limited |
| Sudarshan Padmanabhan | Batlivala & Karani Securities India Pvt. Ltd. |
| Pauline Lau | BofA Global Research |